UNCY News and Press, Unicycive Therapeutics Inc. From 02/02/23

Unicycive Therapeutics ( NASDAQ: UNCY ) signed a license agreement with Lotus Pharmaceutical to develop and commercialize Renazorb in the Republic of Korea. Renazorb (lanthanum dioxycarbonate) is a novel phosphate binding agent being developed by Unicycive to treat hyperphos...

Develops Renazorb opportunity in new market for patients with hyperphosphatemia Agreement includes upfront payment, royalties, and milestone payments LOS ALTOS, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology...

LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foun...

LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four abstracts have been accepted for presentation at the upcoming Internationa...

Unicycive Therapeutics ( NASDAQ: UNCY ) stock rose ~8% on Thursday after the company said it terminated its "at-the-market" (ATM) equity offering program with JonesTrading Institutional Services as sales agent. Unicycive  added that it elected to terminate the offering to...

LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the termination of its “at-the-market” equity offering program (the &#...

Nano-cap biotech Unicycive Therapeutics ( NASDAQ: UNCY ) added ~25% pre-market Wednesday after announcing that its pivotal bioequivalence (BE) study for kidney disease therapy Renazorb met the primary goal. Renazorb is an oral phosphate-binding agent targeted at hyperphosphatemia ...

Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance On track to file New Drug Application mid-2023 LOS ALTOS, Calif., D...

Unicycive Therapeutics ( NASDAQ: UNCY ) said U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) cleared its application seeking to start a phase 1 trial of UNI-494 in healthy volunteers. The MHRA accepted completed review of the clinical trial application ...

LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Ki...